TB-500 + BPC-157 Combo
The internet's favourite research pairing, supplied together in one order. Exactly one controlled experiment has tested whether combining them adds anything, and we quote it below.
Choose your pack
For research use only. Not for human or veterinary use.
What TB-500 + BPC-157 Combo is
The plain-language version, first.
Two famous repair-model compounds in one box, on the strength of a theory.
TB-500 + BPC-157 Combo is a research-use preparation supplying two synthetic peptides together: BPC-157, a 15-residue peptide sequence (GEPPPGKPADDAGLV, approximately 1419.5 Da) derived from a protein in human gastric juice, and TB-500, the acetylated 7-residue thymosin beta-4 fragment Ac-LKKTETQ (approximately 889.0 Da). In the only published controlled comparison, an Achilles tendon transection model in 32 rats, combined administration conferred no additional benefit relative to either agent administered alone.
Some product pages exist because of science. This one exists because of ordering habits.
These two compounds are the most-paired items in the entire research-peptide world. The forums decided they belong together years ago.
So we supply them together. That is a logistics decision, and we are not going to dress it up as a discovery.
The theory behind the pairing is genuinely tidy: BPC-157 gets studied for blood supply reaching damage, TB-500 for cells migrating to it. Supply and movement. Two halves of one repair story.
Tidy theories are where this shelf gets into trouble, so the research section below does something unusual for a combo page.
It quotes the one controlled experiment that actually checked.
What the TB-500 BPC-157 combo research actually shows
Mechanism studied, not outcome promised.
BPC-157 animal work points at VEGF driven angiogenesis. TB-500 binds actin through its LKKTET stretch. Two different front doors into the same repair process, which is what the null result quietly suggests.
In the 2026 Achilles study, TB-500 alone was the only group reaching significance on maximum load to failure. The combination did not. Eight animals per group, so treat it as a pointer and not a verdict.
Both peptides were delivered intraperitoneally as separate injections. That tests the pharmacology of using both. It does not test what happens when the two share a solution, and nobody has published that.
Movement plus supply. The theory is tidy. Tidy is not tested.
The individual mechanisms live on their own pages, and in one sentence each: BPC-157 is studied for angiogenesis, the building of supply routes, and TB-500 for actin dynamics, the machinery of cell movement.
Different mechanisms is the argument for combining them. It is also exactly the kind of argument that sounds airtight and tests poorly.
Biology is not modular the way the theory needs it to be. Two pathways that read as complementary on a whiteboard can be redundant, interfering, or irrelevant to each other in tissue.
Which is why the only thing that settles a combination question is a combination experiment.
Here's the honest part. One exists.
And its result is the reason this page reads the way it does.
The research so far for TB-500 + BPC-157 Combo
Where the evidence is thin, we say so.
Years of separate animal work on each peptide, mostly rodent tendon, muscle and gut models. One controlled head to head comparison of the pair, Bicer 2026, 32 rats, four groups of eight, four weeks, which found no additional benefit from combining them.
Any human trial of the combination. Any second study replicating that null result. Any published work on the two peptides sitting in one solution together. Any approved formulation for either compound, and for BPC-157 a 2026 review counts no completed Phase II clinical trial.
Combination products are usually sold on arithmetic nobody has done. This one is unusual, because the arithmetic finally got done, once, and it came back flat. Bicer and colleagues ran BPC-157, TB-500, and both together against a control in 32 rats with transected and repaired Achilles tendons, and the combined group did not outperform either single agent on histopathology or on biomechanics. The authors attribute this to probable convergence on shared downstream pathways, which is the mechanistically boring explanation and also the most likely one. The study is small and exploratory, and a single null result at eight animals per group is not proof that no combination effect exists under any protocol. What it does mean is that the only evidence anybody can point to runs against the premise this category is sold on, and until a second group replicates it or overturns it, that is the state of the record.
One controlled study looked at the combination. Read what it found.
One controlled animal study has directly tested this combination against its components. Verbatim from it: "Combined BPC-157 and TB-500 did not confer additional benefits compared to either alone."
Did not confer additional benefits. That is the entire controlled literature on the internet's favourite stack, quoted in full.
One rodent study is not a final answer, and it is worth saying the components were studied at particular doses in a particular model. Limits noted.
But the current score is: theory says two is better, the one experiment that checked says it was not.
We sell the combo because researchers order it together. What we will not do is tell you the pairing has evidence behind it when the one direct test points the other way.
Both peptides, one vial. Canadian stock, ships from BC.
TB-500 + BPC-157 Combo specs
The chemistry, exactly as released.
Who studies TB-500 + BPC-157 Combo
Who tends to order this one, and why.
A research compound does not have one audience. It has a handful of rooms where the same question keeps coming up, and the question is a different question in each of them.
Tendon and soft tissue researchers
The Achilles transection model is where the combination literature lives, all one paper of it. If that is the model you run, Bicer 2026 is the direct precedent and it is worth reading before designing around it.
Anyone who wants to replicate a null
A single exploratory study with eight animals per group is exactly the kind of result that needs a second look from an independent group. Nobody has published that second look yet.
Formulation and stability people
Two peptides in one solution, no published compatibility data, and an Asp-Asp motif in BPC-157 that is a known hotspot for aspartimide formation and deamidation. There is real analytical work sitting here for anybody who wants it.
People comparing a blend against singles
This is the rare category where a head to head actually exists. If you are deciding between one blend and two separate vials, the evidence base is one paper long and it is summarised on this page.
Sold for laboratory research only. This is not guidance for personal use, and nothing here is a recommendation.
TB-500 + BPC-157 Combo backstory
How it got here.
These two had nothing to do with each other until a catalogue put them in the same vial. BPC-157 came out of research on proteins in human gastric juice.
The question behind that work was why the stomach lining survives sitting in its own acid all day. A fifteen residue stretch got identified inside a larger protein and synthesised on its own.
TB-500 arrived from a completely different direction. Thymosin beta-4 was isolated from thymus tissue, and later work narrowed its actin binding down to one short internal stretch.
Somebody made just that stretch, acetylated the front end, and Ac-LKKTETQ has carried the TB-500 nickname ever since. The nickname stuck harder than the chemistry name ever did.
The pairing is not a hypothesis anybody published. It is a product category.
It turned up in vendor listings years before anyone ran a controlled test, and when the test finally ran in 2026, the pair did not beat either compound alone.
- 1
A protein that survives its own acid
BPC-157 came out of research into why the stomach lining is not destroyed by gastric acid. The fifteen residue sequence was identified inside a larger protein in gastric juice, then made on its own. It does not exist as a free peptide in nature.
- 2
Seven residues out of forty-three
Thymosin beta-4 was isolated from thymus tissue as a 43 residue protein. Later work narrowed its actin binding to one short stretch. Somebody synthesised just that stretch, capped it with an acetyl group, and Ac-LKKTETQ picked up the name TB-500.
- 3
The vial came before the study
Nobody published a hypothesis that these two belong together. The pairing showed up in catalogues first and got tested years later. When the controlled test finally ran, it found no added benefit from the pair.
Buying TB-500 + BPC-157 Combo in Canada
What ships, how fast, and the paperwork.
The hard part of buying research material is almost never the compound. It is the logistics. What leaves the building, how fast it moves, and what is in the box beside the vial. Here is ours, plainly.
What is actually in the vial
Two synthetic peptides supplied together. BPC-157 at fifteen residues and 1419.5 daltons, TB-500 at seven residues and 889.0 daltons. Neither one is thymosin beta-4 itself, and neither occurs as a free peptide in nature.
A blend makes the analytics harder
Purity methods get validated one analyte at a time. A vial holding two peptides needs a method that resolves both parent peaks plus the degradants of each, so a single combined percentage would not be analytically meaningful even in principle.
Status, said once
Research use only, not for human or veterinary use. WADA lists BPC-157 by name under S0 for 2026, and covers thymosin beta-4 and its derivatives including TB-500 under S2.3. Health Canada named both compounds in its April 2026 advisory on peptides bought online and states that peptides are generally regulated as prescription drugs in Canada. Both sit in the FDA table of bulk drug substances nominated then withdrawn, so neither is on the 503A bulks list.
TB-500 + BPC-157 Combo vs BPC + GHK-Cu + TB-500 Triple Blend
Stacked together constantly, compared almost never.
If two compounds in one vial is the question, three compounds is the escalation, and the evidence trail runs the same direction for both.
This pairing has exactly one controlled study, and it reported no additional benefit over either compound alone. That study is quoted in full on this page.
The triple blend adds GHK-Cu on top, moving from a combination with one negative study to a combination with no studies whatsoever.
More compounds per vial means more theory per fact. Between these two products, the ratio only moves one way. BPC + GHK-Cu + TB-500 Triple Blend has its own page here
Stuff people ask about TB-500 + BPC-157 Combo
If your question is not here, email us. Real human answers.
On the only controlled test that exists, no. Bicer and colleagues compared BPC-157, TB-500, and both together in 32 rats with transected and repaired Achilles tendons in 2026, and reported that combined treatment did not confer additional benefits compared to either agent alone. TB-500 alone was the only group reaching significance on maximum load to failure. One small exploratory study, and also the entire head to head record.
Two synthetic peptides. BPC-157 is fifteen residues, GEPPPGKPADDAGLV, around 1419.5 daltons, a sequence identified inside a protein in human gastric juice. TB-500 is seven residues, Ac-LKKTETQ, around 889.0 daltons, the actin binding stretch of thymosin beta-4 and roughly eighteen percent of that protein by mass. Neither exists as a free peptide in nature.
No, and the two labels get swapped constantly online. Thymosin beta-4 is a 43 residue protein that cells make. TB-500 is residues 17 to 23 of it, synthesised separately and acetylated at the N terminus. Same motif, very different molecule. WADA closes that gap deliberately by covering thymosin beta-4 and its derivatives in a single clause.
The authors of the 2026 study suggest the two may converge on shared downstream pathways. BPC-157 animal work points at angiogenesis and VEGF signalling, TB-500 acts on actin driven cell migration, and both of those feed into the same tissue rebuilding process. Two different entrances into one building. Adding the second entrance does not make the building bigger.
It does not. Both peptides were given intraperitoneally as separate injections over four weeks, so the design tested pharmacological combination rather than co-formulation. There is no published data on how BPC-157 and TB-500 behave sharing one solution. Nothing on compatibility, nothing on stability, and nothing on which pH each of them prefers.
Both are prohibited. The WADA 2026 list names BPC-157 under S0, the non-approved substances category, and S2.3 covers thymosin beta-4 and its derivatives with TB-500 given as the example. USADA states plainly that BPC-157 is prohibited under S0. That clause structure is deliberate, since it captures the full length protein and every fragment of it at once.
Good pairing options with TB-500 + BPC-157 Combo
What researchers stack alongside it.
Pairing is where research gets ahead of itself. These are the compounds researchers put in the same order as TB-500 + BPC-157 Combo, which is a statement about ordering habits, not about evidence. Two things in one cart have not been studied together unless somebody studied them together.
Your body makes exactly one cathelicidin. This is it, all 37 residues, and its lead clinical candidate did not clear phase 2b.
BPC-157's arginate salt sibling. Same fifteen residues, different packaging, and a published literature of its own that rounds to zero.
Order TB-500 + BPC-157 Combo right now
One last look before you decide.
Freeze-dried, COA on the page, ships cold
If you are researching TB-500 + BPC-157 Combo and you want a source you do not have to second-guess, start with the paperwork on this page. For research use only.
Not for human consumption. Not approved by Health Canada or any other regulatory body.
Page last updated August 19, 2026
People also search for TB-500 + BPC-157 Combo
Other names for the same compound.